Karyopharm Therapeutics INC Schedule 13G passive stakes

RA Capital Management, along with affiliated entities, has reported a beneficial ownership of 9.9% of Karyopharm Therapeutics Inc. common stock as of June 30, 2026.

Adage Capital Management, L.P. and associated entities have updated their beneficial ownership filing for Karyopharm Therapeutics Inc., reporting a 6.78% stake.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have updated their beneficial ownership filing for Karyopharm Therapeutics Inc., reporting a 6.3% stake.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G reporting a 6.6% beneficial ownership stake in Karyopharm Therapeutics Inc.

Ikarian Capital, LLC and Neil Shahrestani have filed an exit notice, reporting 0% beneficial ownership in Karyopharm Therapeutics Inc.

Acorn Bioventures and Anders Hove have filed a Schedule 13G reporting a 6.7% beneficial ownership stake in Karyopharm Therapeutics Inc.

Affinity Asset Advisors, LLC and Michael Cho report beneficial ownership of 8.6% of Karyopharm Therapeutics Inc. common stock, including shares from warrant exercises.

Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, has filed a Schedule 13G, reporting beneficial ownership of 8.08% of Karyopharm Therapeutics Inc. common stock.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 5.1% of Karyopharm Therapeutics Inc. common stock as of March 31, 2026.

Opaleye Management Inc., through its affiliate Opaleye, L.P., has reported beneficial ownership of 619,089 shares of Karyopharm Therapeutics Inc. common stock, representing 2.67% of the outstanding shares, exercisable via warrants.

Several entities affiliated with Millennium Management have reported beneficial ownership of Karyopharm Therapeutics Inc. common stock.

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have filed a joint Schedule 13G, indicating a beneficial ownership of 9.99% of Karyopharm Therapeutics Inc. common stock.

Commodore Capital LP and its principals have reported a 9.9% beneficial ownership stake in Karyopharm Therapeutics Inc.

Adage Capital Management, L.P. and its principals reported a 2.38% beneficial ownership stake in Karyopharm Therapeutics Inc. as of December 31, 2025.

Millennium Management LLC and affiliated entities have reported a collective beneficial ownership of 5.5% in Karyopharm Therapeutics Inc. common stock.

Affinity Asset Advisors, LLC and Michael Cho have reported a reduced beneficial ownership stake of 8.6% in Karyopharm Therapeutics Inc., down from 9.99% previously.

Highbridge Capital Management, LLC has reported a 4.9% beneficial ownership stake in Karyopharm Therapeutics Inc. through warrants, subject to a 4.9% ownership blocker.

T. Rowe Price Investment Management, Inc. has reported a 13.8% beneficial ownership stake in Karyopharm Therapeutics Inc. common stock.

J. Wood Capital Advisors LLC and Jason Wood have disclosed a 4.99% beneficial ownership stake in Karyopharm Therapeutics Inc., totaling 1,000,708 shares.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.7% beneficial ownership stake in Karyopharm Therapeutics Inc.

Opaleye Management Inc., Opaleye, L.P., and James Silverman have jointly reported a beneficial ownership of 9.48% in Karyopharm Therapeutics Inc. common stock.

JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.9% in Karyopharm Therapeutics Inc. as of September 30, 2025.

T. Rowe Price Investment Management, Inc. has reported an 8.4% beneficial ownership stake in Karyopharm Therapeutics Inc. common stock.

JPMorgan Chase & Co. has filed a Schedule 13G, revealing a 5.2% beneficial ownership stake in Karyopharm Therapeutics Inc.'s common stock.

Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC have disclosed a combined beneficial ownership of 7.83% of Karyopharm Therapeutics Inc.'s common stock, primarily through equity call options and a convertible bond.

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 5.18% in Karyopharm Therapeutics Inc. as of December 31, 2024.